Skip to content
Head to head

Immunome vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IMNM · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

IMNM -13.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
IMNMVRTX
Snapshot
Sector--Biotechnology
Last price15.69515.02
Change today-5.54%-1.08%
1-year return-10.4%+22.0%
Market cap$1.85B$130.58B
52-week range15.55 – 30.06412.27 – 568.67
Valuation
P/E (TTM)-5.9733.14
P/E percentile, own 5-yr range21st99th
P/B4.086.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.4315.32
Net profit (TTM)$-286.92M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-5947.9%33.1%
Net margin-5593.8%30.7%
Free cash flow (TTM)$-247.71M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership106.3%96.8%
Insider activity (12mo)31 buy / 19 sell28 buy / 22 sell
Short interest (% of float)13.7%1.9%
Analyst consensus90% buy / 10% hold (10)95% buy / 5% hold (21)
Analyst price target$35 (+122%)$624 (+21%)
StockVane view
StockVane Quant RatingD (27)C (68)
Company
Employees1776,400
Founded20061989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.